The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients

Cancer Biology and Therapy

Volumn 13, Issue 12, 2012, Pages 1165-1174

  Tanic, Nikola ^a   Milovanovic, Zorka ^b   Tanic, Nasta ^c   Dzodic, Radan ^b   Juranic, Zorica ^b   Susnjar, Snezana ^b   Plesinac Karapandzic, Vesna ^b   Tatic, Svetislav ^a   Dramicanin, Tatjana ^c   Davidovic, Radoslav ^c   Dimitrijevic, Bogomir ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Acquired resistance; Breast cancer; Endocrine treatment; Immunoexpression, PTEN; Loss of heterozygosity (LOH); Tamoxifen

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PTEN PHOSPHOHYDROLASE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84867137307     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21346     Document Type: Article

References (29)

1. Parkin DM. International variation. Oncogene 2004; 23:6329-40; PMID:15322508; http://dx.doi.org/10.1038/sj.onc.1207726.
2. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance - United States, 1990-2000. MMWR Surveill Summ 2004; 53:1-108; PMID:15179359.
3. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006; 147(Suppl 1):S269-76; PMID:16402113; http://dx.doi.org/10.1038/sj.bjp.0706399.
4. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11:643-58; PMID:15613444; http://dx.doi.org/10.1677/erc.1.00776.
5. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68:826-33; PMID:18245484; http://dx.doi.org/10.1158/0008-5472.CAN-07- 2707.
6. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, et al. Epidermal growth factor receptor/ HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005; 12(Suppl 1):S99-111; PMID:16113104; http://dx.doi.org/10. 1677/erc.1.01005.
7. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207:139-46; PMID:16088978; http://dx.doi.org/10.1002/ path.1829.
8. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-24; PMID:11139588; http://dx.doi.org/10.1074/jbc.M010840200.
9. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-17; PMID:12479367.
10. Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem 2007; 102:1368-74; PMID:17972252; http://dx.doi.org/10.1002/jcb.21593.
11. Pfeiler G, Horn F, Lattrich C, Klappenberger S, Ortmann O, Treeck O. Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression. Oncol Rep 2007; 18:1305-9; PMID:17914589.
12. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005; 18:250-9; PMID:15475931; http://dx.doi.org/10.1038/modpathol.3800296.
13. Leslie NR, Downes CP. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004; 382:1-11; PMID:15193142; http://dx.doi.org/10.1042/BJ20040825.
14. Singh B, Ittmann MM, Krolewski JJ. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosomes Cancer 1998; 21:166-71; PMID:9491329; http://dx.doi.org/10. 1002/(SICI)1098-2264(199802)21:2〈166::AIDGCC13〉3.0.CO;2-P.
15. Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. Oncogene 1998; 17:123-7; PMID:9671321; http://dx.doi.org/10.1038/sj.onc.1201940.
16. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10:8059-67; PMID:15585641; http://dx.doi.org/10.1158/1078-0432.CCR-04-0035.
17. DeGraffenried LA, Fulcher L, Friedrichs WE, Grünwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 2004; 15:1510-6; PMID:15367412; http://dx.doi.org/10.1093/annonc/mdh388.
18. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001; 14:672-6; PMID:11454999; http://dx.doi.org/10.1038/modpathol.3880371.
19. Garcia JM, Silva JM, Dominguez G, Gonzalez R, Navarro A, Carretero L, et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57:237-43; PMID:10617300; http://dx.doi.org/10.1023/A:1006273516976.
20. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999; 9:M57-60; PMID:10611684; http://dx.doi.org/10.1016/S0962-8924(99)01661-X.
21. Breivik J, Gaudernack G. Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol 1999; 9:245-54; PMID:10448112; http://dx.doi.org/10.1006/scbi.1999.0123.
22. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/ Akt for growth. Endocr Relat Cancer 2005; 12:599-614; PMID:16172194; http://dx.doi.org/10.1677/erc.1.00946.
23. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11:359-77; PMID:13499785; http://dx.doi.org/10.1038/bjc.1957.43.
24. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155:1253-60; PMID:10514407; http://dx.doi.org/10.1016/S0002-9440(10)65227-3.
25. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 2000; 53:634-5; PMID:11002770; http://dx.doi.org/10. 1136/jcp.53.8.634.
26. HercepTest™, For determination of HER2 protein overexpression. Catalog Products and Services, DAKO 2007; 86-87.
27. Shi SR, Cote RJ, Wu L, Liu C, Datar R, Shi Y, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem 2002; 50:1005-11; PMID:12133903; http://dx.doi.org/10.1177/002215540205000802.
28. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16:1743-8; PMID:9582022; http://dx.doi.org/10.1038/sj.onc.1200205.
29. Hahn M, Wieland I, Koufaki ON, Görgens H, Sobottka SB, Schackert G, et al. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases. Clin Cancer Res 1999; 5:2431-7; PMID:10499615.